Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.
Jason Hafron, MD
Advertisement
Articles by Jason Hafron, MD
Jason Hafron, MD, revisits the patient profile and discusses factors that inform treatment decision-making in mCSPC.
An expert provides an overview of the types of androgen deprivation therapy (ADT) for mCSPC, other therapies that can be used in combination with ADT for treatment intensification and compares the safety and efficacy of the various regimens.
Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer (mCSPC).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
